Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ruxolitinib XR vs IR in Healthy Participants
NCT06555081Phase 1Completed
- Sponsor
- Incyte
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ruxolitinib in myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD) (2 arms), sponsored by Incyte. Primary endpoint: INCB018424 pharmacokinetic (PK) in Plasma at Day 16. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06555081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555081.